



Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey

Copyright ©The authors 2023

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Received: 3 Aug 2023

Accepted: 20 Sept 2023

To the Editor:

Adherence to medication treatment is crucial for therapeutic success, with nonadherence and nonpersistence in therapy leading to suboptimal outcomes and inappropriate economic burdens on the healthcare system [1]. Targeted biologic therapies have revolutionised severe asthma management, with lessened exacerbations and use of systemic steroids, and improved clinical outcomes and quality of life [2]. However, biologics are costly contributors to healthcare monetary outlays; hence, monitoring patients' adherence and persistence in treatment is crucial.

Barriers to adherence in patients with asthma are various and complex. Patients' beliefs about their medication, such as the perceived need for it, ineffectiveness and safety/tolerability issues, as well as general concerns about medication use and long-term pharmacotherapy, may influence treatment adherence behaviour [3]. Overall adherence to asthma controller medications, which are self-administered daily, is relatively poor [4]. However, adherence to asthma biologics might be different because biologics are administered *via* injection every 2–8 weeks, generally under direct supervision in hospital settings. Moreover, auto-injectable biologics might improve adherence by allowing at-home administration, minimising logistical difficulties and time waste. The availability and actual use of biologics for severe asthma is increasing, yet limited evidence is available about adherence to asthma biologics [5–10].

A survey was designed to investigate patients' beliefs, perspectives, concerns and perceived adherence to their biological therapies and physicians' perspectives on their patients' adherence and commitment to biological anti-asthma treatments. The physician survey questionnaire consisted of 17 closed questions addressing their professional profiles and experience in managing severe asthma, perception of their patient's adherence to both asthma inhalers and biologics and barriers to adherence as well as benefits and concerns regarding auto-administration. The patient survey questionnaire consisted of 35 questions, including general characteristics of respondents, perceived benefits, side-effects and satisfaction with biological treatment, perceived treatment adherence, as well as advantages, drawbacks and barriers to self-administration. The survey questionnaire was designed in the Italian language only and implemented using Research Electronic Data Capture (REDCap). The survey questionnaires were created through a process of consensus among four respiratory physicians (C. Crimi, G.E. Carpagnano, C. Calabrese, M. D'Amato). Pilot testing was performed by the Severe Asthma Network Italy (SANI) network steering committee [11]. Then, a final round of comments and corrections was performed to create the final version. All the authors approved the final version of the surveys, and the full lists of survey questions are available on reasonable request.

Between 15 July and 30 September 2022, SANI secretarial staff emailed the survey web link to representatives of severe asthma patient associations, asking them to distribute the survey among their affiliates. Only those who agreed to participate in the online survey received the link to the 35-question questionnaire. Additionally, this SANI survey was disseminated using the network's channels, such as internal members' newsletters and an open webinar. The data collected were recorded and stored in the REDCap database system hosted at SANI headquarters. The reporting of this survey followed the Checklist for Reporting of Survey Studies [12]. Answering all questions was mandatory, with no blank fields allowed; thus, no imputation for missing data was performed. The overall data were analysed with descriptive statistics (proportions for categorical variables and medians for continuous ones).



Shareable abstract (@ERSpublications)

Patients with severe asthma perceive beneficial effects of biologics and good self-reported adherence to treatment, even when self-administered at home <https://bit.ly/48vP70w>

Cite this article as: Crimi C, Calabrese C, D'Amato M, *et al.* Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey. *ERJ Open Res* 2023; 9: 00560-2023 [DOI: 10.1183/23120541.00560-2023].



190 responses were registered and analysed; 116 from patients and 74 from healthcare providers. 80% of the surveyed patients had severe asthma for >5 years, with 96.5% being treated with biologics for ≥ 2 years (42.1% with mepolizumab, 27.1 with dupilumab, 20.6% with omalizumab, 10.6 with benralizumab). Inhalation therapy while on biological treatment was continued by 89.1% of patients and most believe that it plays a crucial role in their asthma management. More than 95% of the patients confirmed good adherence to their biological medication. More than 80% of them had received detailed information on the biological treatment before starting it. Almost all patients were satisfied, believed they had benefited from it, and wished to continue receiving their biologics (figure 1). Furthermore, >60% of the patient respondents agreed or strongly agreed with the sentence stating “I have discontinued systemic corticosteroids”. Hospital administration was perceived as a burden for one-third of those who did not self-administer their biologics at home, but it had only a minimal impact on patients’ self-reported adherence. However, 85.5% of patients self-administered their biological therapy at home and attended their reference centres (every 6 months for 57.3% of patients) only for routine spirometry, biomarkers and quality-of-life monitoring. More than 60% of patients self-administered the injection, while in approximately one-third it is performed by friends or relatives, and by a nurse in only 5%. Almost all patients are satisfied with self-administration of biologics at home, believe that is easy to perform and would recommend it to other patients. 44% of patients were engaged in patient support programmes, considered helpful by 93.5% of participants and recommended by 73.7% of healthcare providers.

Physicians were mainly allergologists (57.4%) and pulmonologists (41.3%), with the majority (89%) working in public hospitals, and primarily in academic centres (62%). More than half of the healthcare providers reported treating >50 patients with severe asthma per year. More than half of healthcare providers prescribed biological therapies to >70% of their patients with severe asthma, favouring auto-administration in more than half of prescriptions. Nevertheless, only 37.3% of healthcare providers believe that self-administration improves adherence compared with hospital-based administration. More than 80% of healthcare providers were satisfied with their patients’ adherence to biological therapy; satisfaction with inhalation therapy adherence was perceived to be only minimally lower (77.7%). Healthcare providers considered poor awareness of the risks of severe asthma (88%) and fear of adverse effects (57.4%) as the







FIGURE 1 Satisfaction with their biological therapy of surveyed patients with severe asthma.

major drivers of patients' perceived inadequate adherence. In contrast, for most healthcare providers, the prompt improvement of asthma symptoms following biological therapy favours its adherence.

According to 68.6% of surveyed physicians, the subjects who refuse self-administration are afraid that it might be troublesome; a risk also reported by 66.7% of surveyed patients. Simplifying procedures and providing more effective and widespread information emerged as a crucial aspect for the surveyed healthcare providers (26.3%) and patients (26.1%), and it was considered helpful to further boost the already extensive acceptance of biologics self-administration by severe asthma patients.

This was the first cross-sectional study exploring severe asthma patients' self-reported adherence to biologic treatment and auto-administration. These survey findings might help healthcare institutions and policymakers in developing training, educational and monitoring programmes to reduce nonadherence risks in severe asthma patients and identify ideas for other quality improvement programmes. Our study has several limitations. First, estimating response rates to predict the representativeness of the sample was not possible due to the multiple strategies adopted to distribute the survey. Second, the geographical distribution of the responses was not homogeneous. Moreover, treatment adherence was based on patient self-reporting and was not confirmed by objective measures or on-site data validation; this implies that collected data may reflect personal views rather than actual practice. However, patients completed the questionnaires in private and anonymously to answer honestly without worrying about censure. Moreover, as in every survey, the study is assessing perceptions rather than actual data collection on patients. Lastly, we did not measure any patient-related outcomes.

In conclusion, data from this nationwide survey demonstrate that patients' favourable biological treatment attitudes are associated with good self-reported adherence to the treatment. Barriers and concerns of starting self-administration still exist for both patients and physicians; however, patients who experienced self-administration would highly recommend it to other patients and highly value the patient support programmes. In addition, self-administration of biological therapy at home did not impair patients' perceived adherence to the treatment compared with hospital-administration. Specific training, education and programmes to monitor adherence of severe asthma patients should be granted by hospitals, institutions and policymakers. These findings might be helpful in tailoring interventions to increase adherence in individual patients and promote treatment self-administration.

Claudia Crimi ^{1,2}, **Cecilia Calabrese**³, **Maria D'Amato**⁴, **Francesco Blasi**^{5,6}, **Giorgio Walter Canonica** ^{7,8}, **Giuseppe Guida**⁹, **Enrico Heffler**^{7,8}, **Pierluigi Paggiaro** ¹⁰ and **Giovanna Elisiana Carpagnano**¹¹
on behalf of the Severe Asthma Network Italy study group

¹Respiratory Medicine Unit, Policlinico "G. Rodolico-San Marco" University Hospital, Catania, Italy. ²Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy. ³Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy. ⁴Department of Respiratory Medicine, University "Federico II" of Naples, Naples, Italy. ⁵Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy. ⁶Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy. ⁷Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy. ⁸Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Rozzano, Italy. ⁹Severe Asthma and Rare Lung Disease Unit, San Luigi Gonzaga University Hospital - Orbassano, Turin, Italy. ¹⁰Department of Surgery, Medicine, Molecular Biology and Critical Care, University of Pisa, Pisa, Italy. ¹¹Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", Bari, Italy.

Corresponding author: (claudia.crimi@unict.it)

Provenance: Submitted article, peer reviewed.

Acknowledgement: The authors would like to thank the members of the Severe Asthma Network in Italy (SANI), Società Italiana di Allergologia Asma e Immunologia Clinica (SIAAIC), Società Italiana di Pneumologia/Italian Respiratory Society (SIP/IRS) and Global Initiative for Asthma (GINA) Italy working group for their cooperation in disseminating and promoting adherence to this initiative. A special thanks to the following patients' organisations for distributing the survey to patients: AAG (Associazione AsmaGrave Odv), FederAsma e Allergie - Federazione

Italiana Pazienti, and Respiriamo Insieme. The SANI Project was supported by GINA Italy/Federasma/Italian Society of Allergy, Asthma and Clinical Immunology/Italian Respiratory Society.

The SANI study group: E. Bargagli (UOC Respiratory Diseases and Lung Transplantation, Department of Internal and Specialist Medicine, University of Siena, Siena, Italy), R. Barlassina (Pneumologia, Clinica di Malattie dell'Apparato Respiratorio, Università degli studi di Milano, Milan, Italy), B. Beghè (Section of Respiratory Diseases, Department of Medical and Surgical Sciences, Maternal – Infant and Adult, University of Modena and Reggio Emilia, Italy), M. Bonavia (Respiratory Rehabilitation, ASL3, Genoa, Italy), M. Bonini (Department of Cardiovascular and Pulmonary Sciences, Università Cattolica del Sacro Cuore, Rome, Italy), M. Bova (Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy), L. Brussino (SSDDU Immunologia, Ospedale Mauriziano, Allergologia, Turin, Italy), P. Busatto (UO Pneumologia, San Luca Hospital, USL Nordovest Toscana, Lucca, Italy), M.F. Caiaffa (Allergology and Clinical Immunology Unit, University of Foggia, Foggia, Italy), R. Campisi (Respiratory Medicine Unit, Policlinico “G. Rodolico-San Marco” University Hospital, Catania, Italy), C. Cardini (Fondazione Salute Respiratoria, Società Italiana di Pneumologia, Milan, Italy), C. Castagneto (Internal Medicine Department ASL4 Chiavarese, Italy), S. Centanni (Respiratory Unit, ASST Santi Paolo e Carlo, San Paolo Hospital, Department of Health Sciences, University of Milan, Milan, Italy), S. Colantuono (Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy), L. Cosmi (Department of Experimental and Clinical Medicine, University of Firenze, Florence, Italy), S. D’Alò (UOC Allergologia, PO Civitanova Marche, AREA VASTA 3), S. Del Giacco (Unit of Allergy and Clinical Immunology, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy), N.C. Facciolongo (Pulmonology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Italy), E. Favero (Severe Asthma Multidisciplinary Outpatient Clinic, Vittorio Veneto Hospital, Treviso, Italy), M.P. Foschino-Barbaro (Respiratory Unit, Policlinico Riuniti Foggia, and Department of Medical and Surgical Sciences, University of Foggia, Italy), E. Graziani (Ambulatorio Asma e Asma grave Unità di Pneumologia Azienda Ospedaliero-Universitaria Policlinico Umberto I-Sapienza Roma, Rome, Italy), M. Latorre (Pulmonary Unit, Nuovo Ospedale Apuano, Massa, Italy), F. Lodi Rizzini (Allergy and Clinical Immunology Unit, A.O.U. Policlinico “G. Martino”, and Department of Clinical and Experimental Medicine, University of Messina, Italy), F. Losa (UO Allergologia, Immunologia Clinica e Reumatologia, Ospedale Carlo Poma, ASST Mantova, Italy), M. Montagni (Allergy Unit, Guglielmo da Saliceto Hospital, Azienda USL di Piacenza, Italy), S. Nolasco (Respiratory Medicine Unit, Policlinico “G. Rodolico-San Marco” University Hospital, and Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy), E. Nucera (UOSD Allergologia e Immunologia Clinica, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore Roma, Rome, Italy), V. Patella (Department of Internal and Respiratory Medicine, Division of Allergy and Clinical Immunology, “Santa Maria della Speranza” Hospital, Salerno, Italy), C. Pelaia (Department of Health Sciences, University “Magna Graecia” of Catanzaro, Italy), G. Pelaia (Department of Health Sciences, University “Magna Graecia” of Catanzaro, Italy), L. Pini (Department of Clinical and Experimental Sciences, Spedali Civili di Brescia, University of Brescia, Italy), F. Puggioni (Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, and Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Rozzano, Italy), L. Ricciardi (Allergy and Clinical Immunology Unit, A.O.U. Policlinico “G. Martino”, and Department of Clinical and Experimental Medicine, University of Messina, Italy), E. Ridolo (Department of Medicine and Surgery, University of Parma, Italy), G. Scioscia (Department of Medical and Surgical Sciences, University of Foggia, Italy), G. Spadaro (Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy), S. Tripodi (Centro di Malattie Polmonari e Sociali ASP Reggio Calabria, Italy), V. Viviano (ASP Palermo PTA Biondo Area di Allergologia Pneumologia Centro di Riferimento Regionale per la Diagnosi e la Terapia dell’Asma Grave, Italy), M.R. Yacoub (IRCCS San Raffaele Hospital Unit of Immunology Rheumatology Allergy and Rare Diseases, Milan, Italy) and M.C. Zappa (Pulmonology Department, Sandro Pertini Hospital, Rome, Italy).

Conflict of interest: C. Crimi reports support for the present manuscript from GlaxoSmithKline (GSK) and Sanofi; honoraria received for lectures from AstraZeneca, GSK, Sanofi, Novartis, ResMed and F&P, outside the submitted work; and patent pending number 102023000013077 not discussed in the present study. C. Calabrese reports support for the present manuscript from GlaxoSmithKline (GSK) and Sanofi; honoraria received for lectures from AstraZeneca, GSK, Sanofi and Novartis, outside the submitted work; and support for attending meetings and/or travel received from AstraZeneca, GSK, Sanofi and Novartis, outside the submitted work. M. D’Amato reports support for the present manuscript from GlaxoSmithKline and Sanofi. F. Blasi reports support for the present manuscript from GlaxoSmithKline (GSK) and Sanofi; financial grants from AstraZeneca, Chiesi Farmaceutici S.p.A and Insmad Inc. outside the submitted work; consulting fees from Menarini and Zambon outside the submitted work; and speaker fees from AstraZeneca, Chiesi Farmaceutici S.p.A, GSK, Guidotti, Grifols, Insmad Inc., Menarini, Novartis AG, Sanofi-Genzyme, Viatrix Inc., Vertex Pharmaceuticals and Zambon outside the submitted work. G.W. Canonica reports support for the present manuscript from GlaxoSmithKline (GSK) and Sanofi; research grants from A. Menarini, Allergy Therapeutics, AstraZeneca, Chiesi Farmaceutici, Faes, Firma, GSK, Guidotti-Malesci, Hal Allergy, Innovacaremd, Novartis, OmPharma, RedMaple, Sanofi-Aventis, Sanofi-Genzyme, Stallergenes-Greer, Uriach

Pharma, ThermoFisher and Valeas outside the submitted work; honoraria for lectures from A. Menarini, Allergy Therapeutics, AstraZeneca, Chiesi Farmaceutici, Faes, Firma, GSK, Guidotti-Malesci, Hal Allergy, Innovacaremd, Novartis, OmPharma, RedMaple, Sanofi-Aventis, Sanofi-Genzyme, Stallergenes-Greer, Uriach Pharma, ThermoFisher and Valeas outside the submitted work; and advisory board fees from A. Menarini, Allergy Therapeutics, AstraZeneca, Chiesi Farmaceutici, Faes, Firma, GSK, Guidotti-Malesci, Hal Allergy, Innovacaremd, Novartis, OmPharma, RedMaple, Sanofi-Aventis, Sanofi-Genzyme, Stallergenes-Greer, Uriach Pharma, ThermoFisher and Valeas outside the submitted work. G. Guida reports support for the present manuscript from GlaxoSmithKline and Sanofi; and a speaker fee from AstraZeneca outside the submitted work. E. Heffler reports support for the present manuscript from GlaxoSmithKline (GSK) and Sanofi; a research grant from GSK outside the submitted work; fees for lectures from Sanofi, Regeneron, GSK, AstraZeneca, Novartis, Chiesi and Stallergenes-Greer outside the submitted work; and fees for advisory boards participation from Sanofi, Regeneron, GSK, AstraZeneca, Novartis, Chiesi and Stallergenes-Greer outside the submitted work. P. Paggiaro reports support for the present manuscript from GlaxoSmithKline (GSK) and Sanofi; grants for educational events from AstraZeneca, Chiesi Farmaceutici, GSK, Guidotti and Sanofi outside the submitted work; and grants for participation to Advisory Board from AstraZeneca, Chiesi Farmaceutici, GSK, Guidotti and Sanofi outside the submitted work. G.E. Carpagnano reports support for the present manuscript from GlaxoSmithKline (GSK) and Sanofi; and honoraria received for lectures from AstraZeneca, GSK, Sanofi and Chiesi, outside the submitted work.

Support statement: The survey was promoted through webinars organised with the unrestricted support from GlaxoSmithKline and Sanofi.

References

- 1 Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med* 2005; 353: 487–497.
- 2 Agache I, Beltran J, Akdis C, *et al.* Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. *Allergy* 2020; 75: 1023–1042.
- 3 Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. *Psychol Health* 1999; 14: 1–24.
- 4 Wu AC, Butler MG, Li L, *et al.* Primary adherence to controller medications for asthma is poor. *Ann Am Thorac Soc* 2015; 12: 161–166.
- 5 Wu AC, McMahon PM, Welch E, *et al.* Characteristics of new adult users of mepolizumab with asthma in the USA. *BMJ Open Respir Res* 2021; 8: e001003.
- 6 Lafeuille MH, Gravel J, Zhang J, *et al.* Association between consistent omalizumab treatment and asthma control. *J Allergy Clin Immunol Pract* 2013; 1: 51–57.
- 7 Janson SL, Solari PG, Trzaskoma B, *et al.* Omalizumab adherence in an observational study of patients with moderate to severe allergic asthma. *Ann Allergy Asthma Immunol* 2015; 114: 516–521.
- 8 Hosoya K, Komachi T, Masaki K, *et al.* Barrier factors of adherence to dupilumab self-injection for severe allergic disease: a non-interventional open-label study. *Patient Prefer Adherence* 2023; 17: 861–872.
- 9 Campisi R, Crimi C, Intravaia R, *et al.* Adherence to omalizumab: a multicenter “real-world” study. *World Allergy Organ J* 2020; 13: 100103.
- 10 Canonica GW, Rottoli P, Bucca C, *et al.* Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real-life observational PROXIMA study. *World Allergy Organ J* 2018; 11: 33.
- 11 Senna G, Guerriero M, Paggiaro PL, *et al.* SANI – Severe Asthma Network in Italy: a way forward to monitor severe asthma. *Clin Mol Allergy* 2017; 15: 9.
- 12 Sharma A, Minh Duc NT, Luu Lam Thang T, *et al.* A consensus-based Checklist for Reporting of Survey Studies (CROSS). *J Gen Intern Med* 2021; 36: 3179–3187.